美国 · 股市与财经 · Yahoo Finance

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

来源：Yahoo Finance · 美国 11 小时前

Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic…

在 Yahoo Finance 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finance.yahoo.com)

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

推荐阅读

Russia’s Finance Ministry pays wages in digital rubles for first time

I place the world’s top software engineers and interviewed over 10,000 job seekers. The difference on paper and in person is wider than ever

Ukraine’s surprise robot offensive exposes a vulnerability in Putin’s war machine

Middle East crude exports recover to near pre-war levels but oil products still lag, analysts say

Revolut's rise to become Europe's $115 billion big bank rival

‘Digger,’ Warner Bros.’ Last Release Before Merger, Is a Major Flop

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

分享

推荐阅读

Russia’s Finance Ministry pays wages in digital rubles for first time

I place the world’s top software engineers and interviewed over 10,000 job seekers. The difference on paper and in person is wider than ever

Ukraine’s surprise robot offensive exposes a vulnerability in Putin’s war machine

Middle East crude exports recover to near pre-war levels but oil products still lag, analysts say

Revolut's rise to become Europe's $115 billion big bank rival

‘Digger,’ Warner Bros.’ Last Release Before Merger, Is a Major Flop